Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, has received another milestone payment from Boehringer Ingelheim (BI) for progressing a second oncology drug candidate (BI 765049) into the clinic.
 
In this Phase 1 clinical trial, BI 765049, will be administered to patients with advanced solid tumors including colorectal cancer, gastric carcinoma, pancreatic carcinoma, non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma.
 
“The advancement of the second oncology drug candidate, developed under our collaboration with BI, into the clinic is a major validation of our proprietary OGAP® drug discovery platform”, said OBT’s Chief Executive Officer, Dr. Christian Rohlff.  “Selecting the right target is fundamental for the successful development of a first-in-class antibody drug product. OBT’s platforms are designed to discover and engineer antibody constructs to novel therapeutic targets – these include bi-specific, Chimeric Antigen Receptor T Cell (CAR-T), Antibody Drug Conjugate (ADC) and Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics – to best address difficult-to-treat cancers. We believe that the advancement of the first two BI compounds, directed to an oncology target identified by us, into the clinic, further validates our approach.”